PURPOSE: Dose-fractionation schedules of palliative or salvage radiotherapy (RT) for recurrence of non-small-cell lung cancer (NSCLC) are various because they highly depend on patient prognosis. For optimal selection of dose-fractionation schedules, factors affecting survival time after recurrence were examined. MATERIALS AND METHODS: From 1992 to 2005, 115 patients with stage III NSCLC received curative-intent concurrent chemoradiotherapy (CCRT). Among these patients, 74 underwent recurrence and were reviewed. Evaluated factors were age at recurrence, gender, initial stage, histological subtype, initial radiation-field size, recurrent patterns (locoregional alone vs. distant ± locoregional), time to recurrence (≤6 vs. >6 months), and treatment for recurrence (chemotherapy, RT). RESULTS: Median follow-up time after recurrence was 7 (range 0-59) months. One- and 2-year overall survival rates after recurrence were 28 and 11%, respectively. Based on multivariate analysis, time to recurrence (p = 0.0001) and administration of chemotherapy for recurrence (p = 0.0190) were the independently significant factors. CONCLUSIONS: Early recurrence was the most significant factor for survival after post-CCRT recurrence of NSCLC. Administration of chemotherapy for recurrence was also a significant factor, whereas RT for recurrence was not significant. When RT was given to patients with post-CCRT recurrence of NSCLC, dose-fractionated schedules should be determined considering these factors.
PURPOSE: Dose-fractionation schedules of palliative or salvage radiotherapy (RT) for recurrence of non-small-cell lung cancer (NSCLC) are various because they highly depend on patient prognosis. For optimal selection of dose-fractionation schedules, factors affecting survival time after recurrence were examined. MATERIALS AND METHODS: From 1992 to 2005, 115 patients with stage III NSCLC received curative-intent concurrent chemoradiotherapy (CCRT). Among these patients, 74 underwent recurrence and were reviewed. Evaluated factors were age at recurrence, gender, initial stage, histological subtype, initial radiation-field size, recurrent patterns (locoregional alone vs. distant ± locoregional), time to recurrence (≤6 vs. >6 months), and treatment for recurrence (chemotherapy, RT). RESULTS: Median follow-up time after recurrence was 7 (range 0-59) months. One- and 2-year overall survival rates after recurrence were 28 and 11%, respectively. Based on multivariate analysis, time to recurrence (p = 0.0001) and administration of chemotherapy for recurrence (p = 0.0190) were the independently significant factors. CONCLUSIONS: Early recurrence was the most significant factor for survival after post-CCRT recurrence of NSCLC. Administration of chemotherapy for recurrence was also a significant factor, whereas RT for recurrence was not significant. When RT was given to patients with post-CCRT recurrence of NSCLC, dose-fractionated schedules should be determined considering these factors.
Authors: F R Macbeth; J J Bolger; P Hopwood; N M Bleehen; J Cartmell; D J Girling; D Machin; R J Stephens; A J Bailey Journal: Clin Oncol (R Coll Radiol) Date: 1996 Impact factor: 4.126
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Andrea Bezjak; Peter Dixon; Michael Brundage; Dong Tu; Michael J Palmer; Paul Blood; Clive Grafton; Catherine Lochrin; Carson Leong; Liam Mulroy; Colum Smith; James Wright; Joseph L Pater Journal: Int J Radiat Oncol Biol Phys Date: 2002-11-01 Impact factor: 7.038
Authors: Jean-Paul Sculier; Kari Chansky; John J Crowley; Jan Van Meerbeeck; Peter Goldstraw Journal: J Thorac Oncol Date: 2008-05 Impact factor: 15.609
Authors: Khushboo Sharma; Rachel W Goehe; Xu Di; Mark Anthony Hicks; Suzy V Torti; Frank M Torti; Hisashi Harada; David A Gewirtz Journal: Autophagy Date: 2014 Impact factor: 16.016
Authors: Xi Wang; Ping Gao; Fang Lin; Min Long; Yuanyuan Weng; Yongri Ouyang; Li Liu; Junxia Wei; Xi Chen; Ting He; Huizhong Zhang; Ke Dong Journal: Cancer Cell Int Date: 2013-11-14 Impact factor: 5.722